Connect with us

Health

Mary Jane meets Uncle Sam

First medical marijuana dispensary prepares to open in D.C.

Published

on

By DAVE PURDY

Scholars acknowledge George Washington and Thomas Jefferson grew marijuana. President Obama admits he smoked it. George W. Bush and Bill Clinton did, too (well, kind of). Six percent of the U.S. population uses it daily. It’s cheap, has been cultivated since the third millennium B.C., and thrives in almost any soil. Yet, in the United States, it’s still an illegal substance.

All eyes will be on Washington, D.C., when sometime this spring, the first medical marijuana dispensary in our nation’s capital, will open, and authorities predict the Capital City Care Dispensary will be the most regulated in the nation.

The pharmacology of marijuana or cannabis includes tetrahyrocannabinol (THC) – the fun stuff – as well as cannabinoids — the good stuff — which has medicinal properties. Yet, there’s still a stigma associated with the plant, even though scientists throughout the world are eager to explore the therapeutic value of cannabinoids.

One company, Cannabis Science, is developing methods for using cannabis to treat Kaposi’s Sarcoma (KS), the No. 1 cancer around the world, especially in Africa. Experts fear KS is making a comeback because of HIV-related drug resistance. Cannabis Science is raising awareness of the promise of groundbreaking Cannabinoid-based treatment of cancer, including HIV-related cancers such as Kaposi’s Sarcoma, and other medical conditions.

Another company doing research is GW Pharmaceuticals, which is studying how cannabis can be turned into an oral anti-diabetic treatment. Scientists throughout the world today are also exploring using cannabis to treat multiple sclerosis and depression.

Dr. Bob Melamede, founder of Cannabis Science, a publicly traded company told the Blade, “We are now on the verge of proving scientifically what the medical cannabis community has known for decades, that cannabis could be one of our most important treatments for all age-related illnesses as well as for a subset of viral infections including HIV, KSHV and influenza.”

Here’s some interesting data: The CDC estimates there are approximately 1.7 million nosocomial (hospital-associated) infections each year, causing about 100,000 deaths.   Automobile accidents, according to the U.S. Department of Transportation, numbered around 32,000 in 2010. Compare those data with the number of deaths from cannabis overdose:  zero.

So why the stigma associated with cannabis – or with being gay or having HIV or living with mental health issues? Fear. The war on drugs is all about fear.

Eighteen states including the District of Columbia have legalized cannabis for use in patients suffering from glaucoma, nausea and vomiting related to HIV and cancer to stimulate the appetite. In November, voter referenda in Colorado and Washington State approved legalizing its use in general.

The result?  It’s sometimes impossible, and always difficult, to rent property to use for medical marijuana dispensaries and controlled cultivation centers, even in the states where it is legal. Another problem is almost all banks and credit card companies refuse to open accounts for legitimate cannabis businesses.

On the positive side, several nations, including Canada, Austria and Spain, have legalized cannabis for medicinal use, while The Netherlands doesn’t even impose the medical-use-only restriction.

Yet, here in the United States federal law, which trumps state laws, claims “there is no such thing as ‘medical’ marijuana” and “has no currently accepted medical use” in the United States.  President Obama has made clear that going after cannabis users is not a priority of his administration. However, the current federal law is still in place and trumps state laws.

The only way this will change is if Congress passes legislation allowing states to regulate.

Finally, here is the sad part of the cannabis story.  The Food and Drug Admiration has not approved cannabis for any condition or disease in the United States.  With dispensaries opening in Washington, DC we have a unique opportunity to obtain real science by creating a clinical trial network that will give us the important medical and scientific information about cannabis and move from dispensaries to biotech and pharmaceutical support, while saving lives and in the least extend the quality of life for millions.

Dave Purdy is founder and CEO of the World AIDS Institute. Reach him at [email protected].

Advertisement
FUND LGBTQ JOURNALISM
SIGN UP FOR E-BLAST

Health

Office of National AIDS Policy Director Phillips: Congress must increase funding

‘Without congressional funding we can’t get there’

Published

on

The White House in 2011 (Washington Blade photo by Michael Key)

Harold Phillips, director of the White House Office of National AIDS Policy (ONAP), said Monday that Congress must increase funding to end the HIV/AIDS epidemic, including for programs designed around the lives and needs of Americans who are living with the disease.

“We have the support of the Biden-Harris administration, and we have the support at HHS, but without congressional funding we can’t get there,” said Phillips, who delivered his remarks during the AIDS United annual AIDSWatch conference in Washington, D.C.

Phillips echoed remarks by other speakers in calling for Congress to increase appropriations funding for the U.S. Department of Health and Human Services (HHS) Ryan White HIV/AIDS Program, but he also emphasized the importance of “making space for people living with HIV in other aspects of the budget.”

Consistent with the Biden-Harris administration’s focus on employing a whole-of-government approach, Phillips said stakeholders must understand that while “HIV is, yes, a public health threat,” the disease is also “the result of systemic and structural racism,” an intersectional problem requiring more than narrowly focused biomedical or public health responses.

Therefore, he said, these conversations about matters like HIV’s impact on Black lives, or considerations for aging folks who are living with the disease, must be held at places like the White House Gender Policy Council, the National Economic Council, and the U.S. Department of Labor.

“When we talk about ending HIV as a public health threat,” Phillips said, “we also want to end HIV such that it’s not the defining characteristic for people living with HIV and that they can have access to housing, access to employment, good mental health and substance abuse treatment.”

Former ONAP Director Sandra Thurman with ONAP Director Harold Phillips (Screen shot/YouTube)

Under Phillips’s leadership, data on these considerations for those living with HIV/AIDS will be measured for the first time with ONAP’s rollout of new quality of life indicators in the National HIV/AIDS Strategy Federal Implementation Plan.

“There’s an indicator in there that’s self-reported quality of life,” Phillips said, which asks respondents to consider, “how do I feel?” This is important, he added, because people living with HIV may have positive lab results but still feel poorly.

Phillips advised those AIDSWatch participants who are slated to meet with members of Congress and their staffs after hosting a rally on the grounds of the U.S. Capitol Tuesday morning to “build a common bond” with lawmakers by emphasizing the human impact of the appropriations funding for which they are advocating.

An AIDS United spokesperson told the Washington Blade by email Monday that 187 congressional meetings have been scheduled for Tuesday.

Phillips also noted that while “conversations need to happen in Washington, there’s also conversations that need to happen on the state and local level,” where “we’re finding a level of hate and stigma and discrimination that’s on course to try to either stop our progress or take us backwards.”

Speaking before Phillips, Equality Federation Public Health Policy Strategist Mike Webb stressed the importance of policies under consideration by state and local lawmakers. “Our access to PrEP shouldn’t be based on a patchwork of laws by the states,” they said, and HIV-related legislative proposals in many cases would “add criminalizing aspects.”

Laws already on the books that “criminalize the transmission of, or perceived exposure to, HIV and other infectious diseases,” the Movement Advancement Project writes, “create a strong disincentive for being tested for HIV, and result in adverse public health outcomes.”

Phillips and the Biden administration have made modernizing or repealing those laws a top priority.

Continue Reading

Health

Biden budget earmarks funds for HIV along with new programs for PrEP, hepatitis C

Budget seen as preview of Biden’s reelection campaign

Published

on

The White House in 2011 (Washington Blade photo by Michael Key)

The $6.8 trillion budget unveiled by President Joe Biden on Thursday includes increased investment in existing programs to fight HIV/AIDS, along with new initiatives to expand access to HIV prevention medications and eliminate hepatitis C.

U.S. House Republicans are expected to kill the proposal, which is nevertheless seen as a possible blueprint for the major themes to come in Biden’s expected reelection campaign.

Major focus areas of the plan include deficit reduction, increased taxes for the wealthy, and increased spending on the military and other endeavors to compete with China.

The HIV + Hepatitis Policy Institute praised the budget in a press release Thursday, writing that it will “significantly increase the federal resources necessary to end both HIV and hepatitis C.”

The group’s president, Carl Schmid, said Biden “recognizes the historic role the federal government must play, and the investments needed to end infectious diseases.”

First, the plan would bolster funding for the Trump-era Ending the HIV Epidemic in the United States initiative by $313 million, bringing the total to $850 million. Second, it would debut a “ten-year $9.7 billion nationwide PrEP delivery program” and a “historic initiative to eliminate hepatitis C.”

PrEP, or preexposure prophylaxis, is a medication regimen that reduces the risk of contracting HIV. According to the HIV + Hepatitis Policy Institute, only 30 percent of patients who could benefit from the drug are taking it.

The new hepatitis C program “seeks to provide outreach, testing, and curative medications to the estimated 2.4 million people living with hepatitis C, many of whom are unaware of their infection.”

Continue Reading

Health

Gov. Newsom: Calif. will not do business with Walgreens after decision to not distribute abortion pill

20 Republican state attorneys general threatened to sue Walgreens for offering mifepristone

Published

on

Calif. Gov. Gavin Newsom (D) (Washington Blade file photo by Michael Key)

Gov. Gavin Newsom (D-Calif.) announced on Monday that California will not do business with Walgreens following the company’s announcement of its decision on Friday to not distribute the abortion pill mifepristone in 20 states.

The move comes amid pressure from conservative lawmakers and threats of legal action against Walgreens and CVS from 20 Republican state attorneys general, who claimed in a Feb. 1 press release that selling mifepristone is “unsafe and illegal.”

Mifepristone is still legal in several of the states where Walgreens has decided to stop providing it in response to the specter of lawsuits from state attorneys general: Alaska, Iowa, Kansas and Montana.

Newsom’s office told NPR that California will review “all relationships between Walgreens and the state,” but declined to provide more specifics.

“California won’t be doing business with @walgreens – or any company that cowers to the extremists and puts women’s lives at risk,” Newsom wrote in the tweet. “We’re done.”

“Elected officials targeting pharmacies and their ability to provide women with access to safe, effective, and FDA-approved medication is dangerous and just unacceptable,” White House Press Secretary Karine Jean-Pierre said during a briefing on March 3.

“The administration will continue to stand by the FDA’s expert judgment in approving and regulating medications. And in the face of barriers to access and concerns about safety of patients, healthcare providers, and pharmacists, we will continue to support access to this critical medication within the limits of the law,” Jean-Pierre said.

Meanwhile, Judge Matthew Kacsmaryk of the U.S. District Court for the Northern District of Texas is expected to soon rule on a case challenging the safety of mifepristone that advocates for reproductive justice fear could lead to a nationwide injunction prohibiting the sale and distribution of the abortion drug.

Medical experts have slammed the Texas plaintiffs’ lawsuit, arguing that mifepristone’s safety and efficacy have been well demonstrated for years. Kacsmaryk, who was appointed by former President Donald Trump, is nevertheless expected to rule in their favor.

“The plaintiffs who have no legitimate standing have hand-picked him to hear this case that has no merit because they know what they’re getting with Judge Kacsmaryk,” Sen. Ron Wyden (D-Ore.) said last month.

Jean-Pierre addressed the case during a press briefing on March 1: “The decision would be unprecedented, as you know, and devastating to women’s health.  And we may find ourselves in uncharted territory,” she said.

“And so, we’re closely — closely working with the Justice Department and DHS — HHS on this, on how to be prepared for any range of outcome or potential outcomes,” Jean-Pierre added.

Continue Reading
Advertisement
Advertisement

Sign Up for Weekly E-Blast

Follow Us @washblade

Advertisement

Popular